676 related articles for article (PubMed ID: 12930163)
1. Low high-density lipoprotein cholesterol: physiological background, clinical importance and drug treatment.
Hersberger M; von Eckardstein A
Drugs; 2003; 63(18):1907-45. PubMed ID: 12930163
[TBL] [Abstract][Full Text] [Related]
2. Modulation of high-density lipoprotein cholesterol metabolism and reverse cholesterol transport.
Hersberger M; von Eckardstein A
Handb Exp Pharmacol; 2005; (170):537-61. PubMed ID: 16596814
[TBL] [Abstract][Full Text] [Related]
3. Acceleration of reverse cholesterol transport.
von Eckardstein A; Nofer JR; Assmann G
Curr Opin Cardiol; 2000 Sep; 15(5):348-54. PubMed ID: 11128188
[TBL] [Abstract][Full Text] [Related]
4. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
Cziraky MJ; Watson KE; Talbert RL
J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
[TBL] [Abstract][Full Text] [Related]
5. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
Nesto RW
Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
[TBL] [Abstract][Full Text] [Related]
6. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.
Evans M; Roberts A; Davies S; Rees A
Drugs; 2004; 64(11):1181-96. PubMed ID: 15161326
[TBL] [Abstract][Full Text] [Related]
7. Current understanding of the metabolism and biological actions of HDL.
von Eckardstein A; Hersberger M; Rohrer L
Curr Opin Clin Nutr Metab Care; 2005 Mar; 8(2):147-52. PubMed ID: 15716792
[TBL] [Abstract][Full Text] [Related]
8. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
Hausenloy DJ; Yellon DM
Heart; 2008 Jun; 94(6):706-14. PubMed ID: 18480348
[TBL] [Abstract][Full Text] [Related]
9. HDL-C: role as a risk modifier.
Barter P
Atheroscler Suppl; 2011 Nov; 12(3):267-70. PubMed ID: 22152280
[TBL] [Abstract][Full Text] [Related]
10. Role of fibric acid derivatives in the management of risk factors for coronary heart disease.
Després JP; Lemieux I; Robins SJ
Drugs; 2004; 64(19):2177-98. PubMed ID: 15456334
[TBL] [Abstract][Full Text] [Related]
11. High density lipoproteins and arteriosclerosis. Role of cholesterol efflux and reverse cholesterol transport.
von Eckardstein A; Nofer JR; Assmann G
Arterioscler Thromb Vasc Biol; 2001 Jan; 21(1):13-27. PubMed ID: 11145929
[TBL] [Abstract][Full Text] [Related]
12. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
Hausenloy DJ; Yellon DM
Postgrad Med J; 2008 Nov; 84(997):590-8. PubMed ID: 19103817
[TBL] [Abstract][Full Text] [Related]
13. Current, new and future treatments in dyslipidaemia and atherosclerosis.
Chong PH; Bachenheimer BS
Drugs; 2000 Jul; 60(1):55-93. PubMed ID: 10929930
[TBL] [Abstract][Full Text] [Related]
14. Atheroprotective effects of HDL: beyond reverse cholesterol transport.
Feig JE; Shamir R; Fisher EA
Curr Drug Targets; 2008 Mar; 9(3):196-203. PubMed ID: 18336237
[TBL] [Abstract][Full Text] [Related]
15. Beyond LDL-C--the importance of raising HDL-C.
Wierzbicki AS; Mikhailidis DP
Curr Med Res Opin; 2002; 18(1):36-44. PubMed ID: 11999145
[TBL] [Abstract][Full Text] [Related]
16. Bezafibrate. An update of its pharmacology and use in the management of dyslipidaemia.
Goa KL; Barradell LB; Plosker GL
Drugs; 1996 Nov; 52(5):725-53. PubMed ID: 9118820
[TBL] [Abstract][Full Text] [Related]
17. 'Trig-onometry': non-high-density lipoprotein cholesterol as a therapeutic target in dyslipidaemia.
Jacobson TA
Int J Clin Pract; 2011 Jan; 65(1):82-101. PubMed ID: 21105969
[TBL] [Abstract][Full Text] [Related]
18. Have we forgotten the pivotal role of high-density lipoprotein cholesterol in atherosclerosis prevention?
Wierzbicki AS
Curr Med Res Opin; 2005 Feb; 21(2):299-306. PubMed ID: 15802001
[TBL] [Abstract][Full Text] [Related]
19. HDL cholesterol and protective factors in atherosclerosis.
Assmann G; Gotto AM
Circulation; 2004 Jun; 109(23 Suppl 1):III8-14. PubMed ID: 15198960
[TBL] [Abstract][Full Text] [Related]
20. Pharmacologic elevation of high-density lipoproteins: recent insights on mechanism of action and atherosclerosis protection.
Meyers CD; Kashyap ML
Curr Opin Cardiol; 2004 Jul; 19(4):366-73. PubMed ID: 15218398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
